eligibility_summary
Eligible: patients with pathologically confirmed DLBCL, good overall condition with expected survival >6 months, and signed informed consent. Ineligible: concurrent other malignancies, serious medical conditions making participation unsuitable per investigator, pregnant, at risk of pregnancy, or breastfeeding, or poor compliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Study uses 68Ga-grazytracer PET (diagnostic radiopharmaceutical) to image granzyme B released by activated cytotoxic T and NK cells, aiming to predict response to DLBCL immunotherapies. Therapies assessed: (1) CD19-directed CAR‑T cells (engineered autologous T‑cell therapy) that kill CD19+ malignant B cells, (2) Glofitamab (bispecific antibody, CD20×CD3) that binds CD20 on B cells and CD3 on T cells to redirect T‑cell cytotoxicity, (3) iR2 regimen (rituximab anti‑CD20 mAb + lenalidomide IMiD) targeting CD20+ B cells and enhancing T/NK function via cereblon/IKZF degradation and ADCC. Key targets/pathways: granzyme B activity, CD19/CD20 on B cells, CD3/TCR signaling, cereblon‑IKZF axis.